AstraZeneca has announced the licensing-out of two
of its drugs Seroquel and Seroquel XR in Europe and Russia to Cheplapharm
Arzneimittel GmbH.
According to the deal signed between the companies,
AZ will receive an upfront payment of USD 178 Million, in addition to other payments
upon achieving sales milestones.
The patents of the drug variants Seroquel and
Seroquel XR are soon expiring in Europe and Russia. However, the company will
continue to manufacture and provide the drugs, primarily used to treat
schizophrenia and bipolar disorder, to Cheplapharm during the transition
period.
According to a published paper by McGrath J, Saha S, Chant D, Welham J, th...
